Drug delivery, biodistribution and anti-EGFR activity: theragnostic nanoparticles for simultaneous<i>in vivo</i>delivery of tyrosine kinase inhibitors and kinase activity biosensors
Robin Bofinger, Gregory Weitsman, Rachel Evans, Matthias Glaser, Kerstin Sander, Helen Allan, Daniel Hochhauser, Tammy L. Kalber, Erik Årstad, Helen C. Hailes, Tony Ng, Alethea B. Tabor
Abstract
We report the development of targeted theragnostic lipid/peptide/DNA lipopolyplexes for delivery of both a tyrosine kinase inhibitor, and plasmid DNA coding for a biosensor. These are used to quantify EGFR inhibition in cancer cell lines in vivo .
Topics & Concepts
BiodistributionIn vivoTyrosine kinaseDrug deliveryBiosensorChemistryKinasePharmacologyIn vitroMedicineBiochemistryBiologySignal transductionBiotechnologyOrganic chemistryRNA Interference and Gene DeliveryMonoclonal and Polyclonal Antibodies ResearchAdvanced biosensing and bioanalysis techniques